findmyKOL
Clinical trialNCT06529523RecruitingPhase 2Interventional

Tislelizumab in People With Colorectal Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment40Colorectal Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Fiyinfolu O Balogun, MD, PhD

    Memorial Sloan Kettering Cancer Center

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Nigeria
  • Lagos University Teaching Hospital

    Idi-Araba, Lagos, Nigeria

    Not, yet, recruiting
  • Obafemi Awolowo University Teaching Hospital

    Ile-Ife, Nigeria

    Not, yet, recruiting
United States
  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Jul 2024
Primary completion
31 Jul 2028
Completion
31 Jul 2028
Last update posted
7 Oct 2025
Registered enrollment
40
Registry id
NCT06529523

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.